Genmab Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Genmab heeft een totaal eigen vermogen van DKK31.9B en een totale schuld van DKK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk DKK39.7B en DKK7.7B. De EBIT Genmab is DKK6.6B waardoor de rentedekking -6.6 is. Het heeft contanten en kortetermijnbeleggingen van DKK17.3B.

Belangrijke informatie

Verhouding schuld/eigen vermogen

DKK 0

Schuld

Rente dekkingsratio	-6.6x
Contant	DKK 17.32b
Aandelen	DKK 31.92b
Totaal verplichtingen	DKK 7.74b
Totaal activa	DKK 39.66b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Mar 07

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Feb 21

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Nov 13

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Jun 19

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

May 29

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Mar 18

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Feb 27

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Dec 17

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( DKK23.7B ) GMAB } overtreffen de korte termijn passiva ( DKK4.6B ).

Langlopende schulden: De kortetermijnactiva GMAB ( DKK23.7B ) overtreffen de langetermijnschulden ( DKK3.2B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: GMAB is schuldenvrij.

Schuld verminderen: GMAB heeft de afgelopen 5 jaar geen schulden gehad.

Schuldendekking: GMAB heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: GMAB heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Genmab Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

The Price Is Right For Genmab A/S (CPH:GMAB)

Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate

We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated

Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Executive Changes

Co-Founder exercised options to buy kr.45m worth of stock.

Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023)

Consensus EPS estimates fall by 15%

Genmab A/S Takes Full Control of Acasunlimab Development Program

Consensus EPS estimates increase by 14%

Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY

Non-Independent Director recently sold kr.3.8m worth of stock

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Consensus EPS estimates fall by 11%

First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023)

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S' (CPH:GMAB) Price In Tune With Earnings

Genmab A/S Announces Executive Changes

We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope

Executive VP & CFO recently sold kr.22m worth of stock

Executive VP & CFO exercised options to buy kr.22m worth of stock.

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings

Full year 2023 earnings: EPS misses analyst expectations

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?

Genmab A/S Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022)

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Investor sentiment deteriorates as stock falls 16%

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

Co-Founder recently sold kr.58m worth of stock

Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022)

Independent Chairman of the Board recently bought kr.796k worth of stock

With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case

Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching

Co-Founder recently sold kr.57m worth of stock

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven